enfortumab vedotin,ipilimumab,nivolumab,Cabozantinib
seagen,bms,astellas
['gu ', 'vedo', ' vedo', 'crpc', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'biomarker', 'nivo', ' uc,(-ucsd),(-ucsf),']
discussion across gu malignancies to start day at #gu23 biomarkers of response to enfortumab vedotin in uc, cabo/nivo in rcc, updated analysis of nivo/ipi of crpc - high tmb not predictive of benefit and new clinical risk stratification for relapse in stage 1 seminoma 
Assistant Professor Harvard Medical School; Director of Clinical Research, Lank Center for GU Oncology DFCI COI -coi.asco.org/share/EXE-GEFM…